Choosing a PDMO^® for your programme

Infographic1 min read 19th Jul 2021

Share via email Share via LinkedIn

Choosing a PDMO® for your programme

Share via email Share via LinkedIn

Popular articles

Photo of Mike McCoy, Director of Toxicology and Industrial Hygiene

Blog7 min read

De-risking HPAPI scale-up: common pitfalls and practical solutions Read more

Preview of Sterling Pharma Solutions' ADC case study about a project involving DMA

Poster Presentation8 min read

When ADC meets DMA: Uncovering unexpected critical parameters Read more

Preview of Sterling Pharma Solutions' ADC case study about a Veraxa project

Poster Presentation6 min read

Transfer, simplify, scale: ADC partnership development Read more

Building quality by design: How CPP and PAR studies ensure safe and scalable API manufacturing

Whitepaper5 min read

Building quality by design: How CPP and PAR studies ensure safe and scalable API manufacturing Read more

Whitepaper7 min read

Scaling ring-closing metathesis in API development: Challenges and success factors Read more

ADC manufacturing facilities at Sterling Pharma Solutions' Deeside, Wales facilities

Blog7 min read

Top 5 considerations in ADC clinical manufacturing Read more

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

LinkedIn

This field is for validation purposes and should be left unchanged.

Name(Required)

Email(Required)

Company Name(Required)

This field is hidden when viewing the form

Prospect Source

Please click here for our privacy policy

Service. Passion. Science.

PDMO^® is registered in the U.S. Patent and Trademark Office.

PDMO^® is a registered trademark of Sterling Pharma Solutions Limited (EUIPO and UKIPO). All rights reserved.

Sterling Pharma Solutions Limited. Registration number: 05712796. Registered office address: Dudley Lane, Dudley, Cramlington, NE23 7QG, United Kingdom. Registered in England.
VAT number: GB320549229